MA41296A - Procédés de transdifférenciation et procédés d'utilisation de ceux-ci - Google Patents

Procédés de transdifférenciation et procédés d'utilisation de ceux-ci

Info

Publication number
MA41296A
MA41296A MA041296A MA41296A MA41296A MA 41296 A MA41296 A MA 41296A MA 041296 A MA041296 A MA 041296A MA 41296 A MA41296 A MA 41296A MA 41296 A MA41296 A MA 41296A
Authority
MA
Morocco
Prior art keywords
methods
same
transdifferentiation
processes
transdifferentiation processes
Prior art date
Application number
MA041296A
Other languages
English (en)
Inventor
Sarah Ferber
Original Assignee
Orgenesis Ltd
Tel Hashomer Medical Res Infrastructure & Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orgenesis Ltd, Tel Hashomer Medical Res Infrastructure & Services Ltd filed Critical Orgenesis Ltd
Publication of MA41296A publication Critical patent/MA41296A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
MA041296A 2014-12-30 2015-12-29 Procédés de transdifférenciation et procédés d'utilisation de ceux-ci MA41296A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462098050P 2014-12-30 2014-12-30

Publications (1)

Publication Number Publication Date
MA41296A true MA41296A (fr) 2017-11-07

Family

ID=56284403

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041296A MA41296A (fr) 2014-12-30 2015-12-29 Procédés de transdifférenciation et procédés d'utilisation de ceux-ci

Country Status (15)

Country Link
US (3) US10179151B2 (fr)
EP (2) EP3698803B1 (fr)
JP (1) JP6817943B2 (fr)
KR (1) KR102487883B1 (fr)
CN (1) CN107750170B (fr)
AU (1) AU2015373129B2 (fr)
BR (1) BR112017014280A2 (fr)
CA (1) CA2972569A1 (fr)
CO (1) CO2017006937A2 (fr)
EA (1) EA035360B1 (fr)
IL (1) IL253234B (fr)
MA (1) MA41296A (fr)
MX (1) MX378321B (fr)
SG (1) SG11201705344VA (fr)
WO (1) WO2016108237A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015031253B1 (pt) 2013-06-13 2021-09-28 Orgenesis Ltd. Método para produção de uma população de células transdiferenciada
JP6749239B2 (ja) 2013-09-24 2020-09-02 ガイナー ライフ サイエンシズ，インク． 細胞インプラントのガス処理用システム
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
US10988724B2 (en) 2016-05-05 2021-04-27 Southwest Research Institute Three-dimensional bioreactor for cell expansion and related applications
EP3541449B1 (fr) 2016-11-15 2021-11-10 Giner Life Sciences, Inc. Dispositif de diffusion de gaz percutané adapté pour utilisation avec un implant sous-cutané
US11642501B2 (en) 2017-05-04 2023-05-09 Giner, Inc. Robust, implantable gas delivery device and methods, systems and devices including same
EP3635106A4 (fr) * 2017-05-08 2021-01-06 Orgenesis Ltd. Populations de cellules transdifférenciées et leurs procédés d'utilisation
WO2018220623A1 (fr) * 2017-05-29 2018-12-06 Orgenesis Ltd. Compositions et procédés de fourniture de thérapie de remplacement cellulaire
JP2020537522A (ja) 2017-10-13 2020-12-24 イーエムベーアー−インスティテュート フュール モレクラレ バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 体細胞の増強された再プログラミング
US20210171915A1 (en) * 2018-03-06 2021-06-10 Orgenesis Inc. Three dimensional clusters of transdifferentiated cells, compositions and methods thereof
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
SG11202102986XA (en) 2018-09-24 2021-04-29 Southwest Res Inst Three-dimensional bioreactors
EP3816276A1 (fr) * 2019-10-31 2021-05-05 Unicyte Islet AG Structures de cellules de type îlots pancréatiques viables et leur procédé de préparation
JP2024539612A (ja) 2021-10-28 2024-10-29 サウスウエスト リサーチ インスティテュート 細胞分離のためのデバイス

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427940A (en) 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
WO1994008598A1 (fr) 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Cellules hepatiques de reserve
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2169631C (fr) 1993-08-16 2005-01-11 Marc R. Montminy Nouveau facteur de boite homeo qui stimule l'expression de l'insuline dans les cellules des ilots pancreatiques
US5858973A (en) 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
RU2178714C2 (ru) 1995-11-30 2002-01-27 Рисерч Дивелопмент Фаундейшн Скрининг-анализ соединений, стимулирующих продуцирование соматостатина и инсулина
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
CA2258499A1 (fr) 1996-06-24 1997-12-31 Kevin G. Ferreri Procedes destines a l'isolation et a la proliferation de cellules secretant de l'insuline
EP0996736A1 (fr) 1997-08-11 2000-05-03 Chiron Corporation Methodes de modification genetique de lymphocytes t
CA2221195A1 (fr) 1997-11-14 1999-05-14 Chantal E. Holy Matrice en polymere biodegradable
US6143293A (en) 1998-03-26 2000-11-07 Carnegie Mellon Assembled scaffolds for three dimensional cell culturing and tissue generation
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6774120B1 (en) 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6716824B1 (en) 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
US6759039B2 (en) 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
US7214371B1 (en) 2000-09-01 2007-05-08 Ben-Gurion University Of The Negev Research & Development Authority Tissue engineered biografts for repair of damaged myocardium
US7524492B2 (en) 2001-08-31 2009-04-28 Joslin Diabetes Center, Inc. Insulin related transcription factor and uses thereof
WO2003033697A1 (fr) 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Transformation de cellules souches et progenitrices du foie en cellules fonctionnelles du pancreas
US7722894B2 (en) 2001-10-22 2010-05-25 Massachusetts Institute Of Technology Biodegradable polymer
US7033831B2 (en) 2001-12-07 2006-04-25 Geron Corporation Islet cells from human embryonic stem cells
WO2003072728A2 (fr) 2002-02-22 2003-09-04 University Of Florida Trans-differenciation cellulaire
GB0206357D0 (en) 2002-03-18 2002-05-01 Univ Bath Cells
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
BR0311360A (pt) 2002-05-28 2006-06-06 Becton Dickinson Co métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina
EP1620140B1 (fr) 2003-05-05 2013-10-09 Ben-Gurion University Of The Negev Research And Development Authority Preparations polymeres reticulees injectables et leurs utilisations
EP1624898A1 (fr) 2003-05-12 2006-02-15 Sarah Ferber Procedes d'induction d'une production regulee de l'hormone pancreatique dans des ilots non pancreatiques
EP1649000A4 (fr) 2003-06-30 2008-04-30 Lifescan Inc Ensemencement de cellules pancreatiques sur des matrices poreuses
EP1670900A4 (fr) 2003-08-27 2008-06-11 Stemcells California Inc Populations de cellules progenitrices et de cellules souches pancreatiques enrichies, methodes d'identification, d'isolement et d'enrichissement de ces populations
EP1697494B1 (fr) 2003-12-09 2012-02-22 Ben-Gurion University Of The Negev Research And Development Authority Bioreacteur a perfusion a milieu d'impulsion avec moyen de transport de masse ameliore pour constructions cellulaires 3d multiples
EP1784481A1 (fr) 2004-08-25 2007-05-16 Technion Research And Development Foundation, Ltd. Procédé de génération de corps embryoïdes utilisant des échelles tridimensionnelles
WO2006092799A1 (fr) 2005-03-02 2006-09-08 Polyrizon Ltd. Procede de retrait de toxines de membranes mucosales
US9216236B2 (en) 2005-03-07 2015-12-22 Technion Research & Development Foundation Limited Natural tissue-derived decellularized matrix and methods of generating and using same
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2008013737A2 (fr) * 2006-07-19 2008-01-31 University Of Florida Research Foundation, Inc. Compositions pour la reprogrammation d'une cellule et leurs utilisations
AU2007335753B2 (en) 2006-12-18 2013-12-05 Ben Gurion University Of The Negev Scaffolding for tissue regeneration or repair
WO2009007979A2 (fr) 2007-07-11 2009-01-15 Technion Research & Development Foundation Ltd. Cellules souches mésenchymateuses encapsulées et leurs procédés d'utilisation
IL187707A0 (en) 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
WO2009126927A2 (fr) * 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Procédés de génération de cellules produisant de l'insuline
US9683215B2 (en) 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
US20120210451A1 (en) 2009-08-02 2012-08-16 Hirofumi Shimizu Islet cell sheet, process for production thereof, and use thereof
LT2494039T (lt) * 2009-10-31 2019-07-25 Genesis Technologies Limited Ląstelių perprogramavimo būdai ir jų panaudojimas
JP2011223993A (ja) 2010-03-30 2011-11-10 Kumamoto Univ 幹細胞の分化誘導方法
EP2580320B1 (fr) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogrammation de cellules pour leur conférer un nouveau destin
WO2013021389A2 (fr) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Régulation à la baisse de mir-7 pour favoriser la différenciation des cellules bêta et la production d'insuline
WO2013124855A1 (fr) 2012-02-21 2013-08-29 Ben-Gurion University Of The Negev Research And Development Authority Système hydrogel comprenant des polypeptides bioactifs séparés dans l'espace
US9993497B2 (en) 2012-12-30 2018-06-12 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
DK2994528T3 (da) 2013-05-08 2024-02-05 Prokidney Organoider, der omfatter isolerede renale celler og anvendelser deraf
BR112015031253B1 (pt) 2013-06-13 2021-09-28 Orgenesis Ltd. Método para produção de uma população de células transdiferenciada
EP3107549B1 (fr) 2014-02-20 2020-07-01 B.G. Negev Technologies and Applications Ltd. Polyplexes anioniques destinés à être utilisés pour l'administration d'acides nucléiques
WO2015184313A1 (fr) 2014-05-30 2015-12-03 Secant Medical, Inc. Préparations de matériaux polymères à médiation par l'eau
EP3149026B1 (fr) 2014-06-02 2025-03-05 B.G. Negev Technologies and Applications Ltd. Modification régiosélective de polysaccharides et applications associées
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
KR20180104646A (ko) 2016-01-07 2018-09-21 비.지. 네게브 테크놀로지즈 앤드 애플리케이션스 리미티드, 엣 벤-구리온 유니버시티 면역관용 반응을 구축하기 위한 조성물 및 방법
US20170290954A1 (en) 2016-04-07 2017-10-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Compositions and methods for treating spinal cord injury
WO2017175229A1 (fr) 2016-04-07 2017-10-12 B.G. Negev Technologies And Applications Ltd. Compositions de polysaccharides et leurs utilisations
EP3635106A4 (fr) 2017-05-08 2021-01-06 Orgenesis Ltd. Populations de cellules transdifférenciées et leurs procédés d'utilisation

Also Published As

Publication number Publication date
KR102487883B1 (ko) 2023-01-11
EP3698803B1 (fr) 2023-03-08
JP6817943B2 (ja) 2021-01-20
AU2015373129B2 (en) 2021-07-15
CO2017006937A2 (es) 2017-10-20
EA035360B1 (ru) 2020-06-02
EP3240576B1 (fr) 2020-03-04
SG11201705344VA (en) 2017-07-28
BR112017014280A2 (pt) 2018-03-27
US10179151B2 (en) 2019-01-15
US20200297777A1 (en) 2020-09-24
CN107750170A (zh) 2018-03-02
EP3698803A1 (fr) 2020-08-26
EA201791508A1 (ru) 2018-05-31
US20160220616A1 (en) 2016-08-04
EP3240576A1 (fr) 2017-11-08
MX378321B (es) 2025-03-10
AU2015373129A1 (en) 2017-08-03
US11617769B2 (en) 2023-04-04
CN107750170B (zh) 2021-10-08
KR20170102308A (ko) 2017-09-08
IL253234B (en) 2020-04-30
US20190134097A1 (en) 2019-05-09
WO2016108237A1 (fr) 2016-07-07
EP3240576A4 (fr) 2018-06-20
MX2017008669A (es) 2018-02-16
JP2018502574A (ja) 2018-02-01
CA2972569A1 (fr) 2016-07-07
IL253234A0 (en) 2017-08-31
US10668107B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
IL259837A (en) Microfluidic devices and kits and their uses
EP3545085A4 (fr) Systèmes crispr/cpf1 et méthodes
KR102478638B9 (ko) 진단 방법 및 이를 수행하는 기기
MA55748A (fr) Procédés de détection d'aav
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
PL3301990T3 (pl) Sposób i przyrząd do ustanawiania powiązania
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
IL247458A0 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3688132A4 (fr) Solutions de décapage et procédés d'utilisation de solutions de décapage
ME03417B (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP3515503A4 (fr) Lymphocytes modifiés
TWI561924B (en) Chemically-amplified negative resist composition and resist patterning process using the same
PL3392931T3 (pl) Separator dla urządzenia elektrochemicznego i urządzenie elektrochemiczne go zawierające
EP3515897A4 (fr) Carbamates de pipérazine, procédés de préparation et utilisation de ceux-ci
TWI561931B (en) Chemically-amplified positive resist composition and resist patterning process using the same
MA46059A (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
EP3426262A4 (fr) Agents de réticulation et procédés associés
EP3303436A4 (fr) Hydrofluorooléfines et leurs procédés d'utilisation
EP3433587A4 (fr) Balance et procédés associés
MA45047A (fr) Procédés d'utilisation d'inhibiteurs de fasn
EP3334522A4 (fr) Adsorbants et procédés de fabrication et d'utilisation d'adsorbants
MA45326A (fr) Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
EP3500219A4 (fr) Attelle physiothérapique et procédés associés